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Abstract
Mitochondrial reactive oxygen species (ROS) are involved in diabetic liver disease 
development. Diabetes impairs complex I activity and increases ROS production in 
liver mitochondria. The complex I produces ROS in forward electron transfer (FET) 
or in reverse electron transfer (RET) modes depending on the site of electron transfer 
blocking and the availability of respiratory substrates. Complex I activity depends 
on the phospholipid cardiolipin and the redox state of reactive thiols in the enzyme. 
Neither the underlying factors leading to complex I dysfunction nor the mode of ROS 
production have been elucidated in liver mitochondria in diabetes. We tested in liver 
mitochondria from streptozotocin (STZ) -induced diabetic rats if the addition of car-
diolipin or β-mercaptoethanol, a thiol reducing agent, recovers complex I activity and 
decreases ROS production with substrates inducing ROS production in FET or RET 
modes. Decreased complex I activity and enhanced ROS generation in FET mode was 
detected in mitochondria from diabetic rats. Complex I activity was fully restored 
with the combined treatment with cardiolipin plus β-mercaptoethanol, which also 
abated ROS generation in FET mode. This suggest that therapies restoring cardiolipin 
and reducing mitochondrial thiols might be useful to counteract impaired complex I 
activity and excessive ROS production in liver mitochondria in diabetes.
Keywords: diabetes, liver disease, electron transport chain, free radicals, NADH 
dehydrogenase
1. Introduction
Hyperglycemia causes liver injury in diabetic rats by inducing apoptosis via 
ERK1/2, p38, and NF-κB pathways [1]. These proteins can be activated by ROS [2]. 
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The sources of ROS in the diabetic liver includes activated NADPH oxidases [3] and 
the mitochondrial electron transport chain (ETC) [4]. Mitochondrial ROS are essen-
tial for the development diabetic liver injury, as evidenced by the therapeutic effect 
of mitochondria-targeted antioxidants on non-alcoholic fatty liver disease (NAFLD) 
[5], which is the manifestation of liver disease in the metabolic syndrome [6].
Diabetes impairs complex I activity in the ETC of liver mitochondria, leading 
to electron leak and increased ROS production [7–9]. The complex I is a large, 
L-shaped, multimeric protein that oxidizes NADH via a flavin mononucleotide 
(FMN) located at the soluble arm of the complex. Electrons are transferred then 
through a series of Fe-S clusters to a ubiquinone molecule placed in a binding site 
at the interface of the soluble and membrane arms of the complex I [10]. Complex 
I activity depends on interactions with the anionic phospholipid cardiolipin, 
enabling the access of ubiquinone molecules to its binding site and stabilizing the 
formation of channels for protonation pathways in the ubiquinone-binding site 
[11]. Lipid peroxidation, a key feature in the diabetic liver [12], modifies the spatial 
orientation of cardiolipin in the inner mitochondrial membrane, altering specific 
interactions between protein domains and cardiolipin [13]. Therefore, lipid per-
oxidation may disrupt electron transfer in the complex I by impairing cardiolipin 
function. Another factor decreasing complex I activity is the reversible oxidation of 
reactive thiols, which occurs by a drop in the ratio of reduced-to-oxidized glutathi-
one (GSH/GSSG) in mitochondria. Complex I activity can be recovered by increas-
ing the levels of GSH with a thiol reducing agent [14].
Decreased complex I activity lead to increased mitochondrial ROS production. ROS 
are produced in FET mode when NADH is oxidized by FMN but electron transfer is 
blocked at the ubiquinone-binding site in the complex I [15]. ROS may be also produced 
in RET mode when high succinate concentrations reduces the pool of ubiquinone and 
forces reverse electron flow from the ubiquinone-binding site to the FMN [16].
Previously, we have observed that diabetes exacerbates lipid peroxidation 
and decreases GSH/GSSG ratio in liver mitochondria [9]. As these events causes 
oxidative damage in cardiolipin and the oxidation of thiol groups in the complex I, 
respectively, the hypothesis of this study is that impaired complex I activity in liver 
mitochondria of diabetic rats may be restored by the in vitro treatment with cardio-
lipin and a thiol reducing agent. To address this hypothesis, we have treated isolated 
liver mitochondria from type 1, STZ-induced diabetic rats with β-mercaptoethanol, 
a thiol reducing agent [17], or with exogenous cardiolipin, which restitutes normal 
cardiolipin levels in mitochondria [18]. The results show that β-mercaptoethanol 
or cardiolipin partially restored complex I activity, while the combination of these 
agents fully recovers complex I activity. Moreover, diabetes increased ROS produc-
tion in the complex I only in FET mode, which was inhibited by the combined treat-
ment with β-mercaptoethanol plus cardiolipin. These results are discussed in the 
context of known structure–activity relationships for complex I and the importance 
of impaired liver metabolism in the development of insulin resistance.
2. Materials and methods
2.1 Animals and experimental groups
Male Long-Evans rats weighing 300–350 g were housed in a bioterioum with 
controlled temperature and 12 h/12 h dark/light cycles. The rats were fed ad libitum 
with a standard rodent chow (Laboratory Rodent Diet 5001, LabDiet, St. Louis, 
MO, USA) plus free access to water. Before diabetes induction, the animals were 
fasted overnight. Type 1 diabetes was induced by an intraperitoneal injection of 
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45 mg/Kg STZ. Five days later, blood glucose was measured and the animals with 
glucose levels ≥150 mg/dL were selected for the study. Blood glucose levels were 
assessed with an Accu-Chek glucometer (Roche DC México S.A de C.V.). All the 
procedures with animals were carried out in accordance with Federal Regulations 
for the Use and Care of Animals (NOM-062-ZOO-1999) issued by the Mexican 
Ministry of Agriculture.
2.2 Mitochondria isolation
After 90-days diabetes, rats were fasted by 12 h before the sacrifice. Rats were 
decapitated, the liver was extracted, weighted, and placed in a medium with 
220 mM mannitol, 70 mM sucrose, 2 mM MOPS and 1 mM EGTA (pH 7.4). The 
liver was cut in small fragments, washed, and homogenized with in a Potter-
Elvehjem homogenizer. The liver homogenate was centrifuged at 314 x g for 10 min. 
The supernatant was recovered and centrifuged at 4410 x g for 10 min. From this 
centrifugation, the supernatant was discarded, and the pellet was washed and 
resuspended with a medium containing 220 mM mannitol, 70 mM sucrose and 
2 mM MOPS (pH 7.4), and centrifuged at 6350 x g for 10 min. Finally, supernatant 
from the later centrifugation was discarded and the pellet was resuspended in 
500 μL of the latter medium. All the centrifugations were carried out at 4°C. The 
concentration of mitochondrial protein was assessed by the Biuret method.
2.3 Addition of cardiolipin to isolated mitochondria
Cardiolipin liposomes were fused with liver mitochondria to increase the con-
tent of this phospholipid in mitochondrial membranes as reported elsewhere [18]. 
Briefly, 1.7 mg cardiolipin (Sigma-Aldrich, St. Louis, MO, USA) was added to 1 mL 
25 mM KH2PO4 (pH 6.7). To obtain liposomes, this mixture was subjected to six 
cycles of sonication at 40 W for 2.5 min each with a Branson 450 sonifier (Branson 
Ultrasonics, Danbury, CT USA) under a N2 stream. Then, 1 mL of freshly prepared 
liposomes were mixed with 1 mg mitochondrial protein in 25 mM KH2PO4 buffer 
with constant stirring for 40 min. Mitochondria were centrifuged at 13684 x g for 
20 min to eliminate cardiolipin excess. Mitochondria were resuspended in 25 mM 
KH2PO4 buffer, and centrifuged again for 10 min at 13684 x g. The pellet was recov-
ered and resuspended in a medium with 250 mM sucrose and 10 mM Tris (pH 7.4).
2.4 Measurement of complex I activity and treatments with β-mercaptoethanol
Mitochondria were solubilized with Triton X-100 as reported previously [9]. 
Detergent-solubilized mitochondrial protein (0.1 mg/mL) was placed in a quartz 
cuvette with 1 mL 50 mM KH2PO4 buffer (pH 7.6) and incubated with 1 mM KCN 
and 1 μg antimycin A. After 5 min, 5 mM potassium ferricyanide was added as elec-
tron acceptor and the absorbance was registered at 340 nm for 1 min in a Shimadzu 
UV2550 spectrophotometer (Kyoto, Japan). Next, 1 mM NADH was added and the 
changes in the absorbance were further registered for 4 min. Complex I activity was 
calculated from the slopes of the time-traces of NADH oxidation. Mitochondria 
fused with cardiolipin liposomes were used to determine the effect of exogenously 
added cardiolipin on complex I activity. For complex I determinations in the pres-
ence of a thiol reductant, mitochondria were incubated 15 min before complex I 
assay in 50 mM KH2PO4 buffer (pH 7.6) with 25 or 50 μM β-mercaptoethanol [19]. 
To evaluate the effect of cardiolipin plus β-mercaptoethanol on complex I activity, 
mitochondria were first fused with cardiolipin liposomes and then treated with 
50 μM β-mercaptoethanol by the procedures described above.
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2.5 Determination of ROS production
ROS generation was assessed in isolated mitochondria by measuring the oxida-
tion of the fluorescent probe 2′,7′-dichlorodihydrofluorescein (H2DCF) as previ-
ously described [9], except that some modifications in the experimental conditions 
were made to identify the mode by which ROS were produced. To assess ROS 
production in complex I by FET mode, 10 mM glutamate-malate was added as sub-
strate and the fluorescence of H2DCF was followed for 20 min. To determine ROS 
production in the complex I by RET mode, 10 mM succinate was added as substrate 
and the fluorescence was followed for 20 min. ROS production upstream complex I 
(i.e. in the complex II - complex IV segment of the ETC) was assessed by inhibiting 
RET with rotenone, a complex I inhibitor, and using succinate as substrate [16], 
after which the changes in fluorescence were evaluated for 20 min. The rate of ROS 
generation was expressed like the change in arbitrary units of fluorescence (ΔF) per 
min−1 per mg mitochondrial protein−1.
2.6 Statistical analysis
The number of independent experiments using different samples is indicated 
in the legend to each figure. The results are expressed as the mean ± standard 
error. Statistical differences between means were analyzed with Student’s t-test 
(P < 0.05), using the Sigma Plot (v11.0) software (Systat Software, Inc., San Jose, 
CA, USA).
3. Results
3.1 Blood glucose and relative liver weight
After 90 days of diabetes induction, blood glucose levels in control and diabetic 
rats were 98.2 and 347.1 mg/dL, respectively, (Figure 1A). Moreover, the liver 
weight in diabetic rats was 1.3- fold higher than in control rats (Figure 1B). This 
effect was more accentuated when liver-to-body weight ratios were compared, as 
the value of this parameter was almost two - fold higher in the diabetic rats than in 
the control animals (Figure 1C). These results confirm the presence of hyperglyce-
mia and a pathologic phenotype in the livers of STZ-induced diabetic rats.
3.2 Effects of β-mercaptoethanol and cardiolipin on complex I activity
The effect of diabetes on complex I activity of liver mitochondria is shown in 
the Figure 2. Complex I activity was 1.8 – fold lower in the mitochondria of diabetic 
rats than in mitochondria from the control group. On the other hand, isolated mito-
chondria from diabetic rats were incubated with 25 or 50 μM β-mercaptoethanol 
to evaluate at what extent thiol reduction recovers the activity of the complex 
I (Figure 2A). Both β-mercaptoethanol concentrations partially recovered the 
enzymatic activity, being this effect statistically significant only with 50 μM of 
β-mercaptoethanol. Thus, 50 μM of β-mercaptoethanol was chosen for the follow-
ing experiments. Of note, β-mercaptoethanol concentrations higher than 50 μM 
impaired complex I activity (data not shown).
Liver mitochondria from diabetic rats were incubated with cardiolipin to deter-
mine at what extent this phospholipid recovers complex I activity in diabetic rats 
(Figure 2B). It can be observed that cardiolipin addition restored complex I activity 
5
Thiol Reduction and Cardiolipin Improve Complex I Activity and Free Radical Production…
DOI: http://dx.doi.org/10.5772/intechopen.95112
Figure 1. 
Effects of diabetes on blood glucose levels (A), liver weight (B) and relative liver weight (C). Data are 
presented as the mean ± standard error of n ≥ 4. *P < 0.05 vs. control group (Student’s t-test).
Figure 2. 
Recovery of complex I activity in liver mitochondria from diabetic rats by the incubation with 
β-mercaptoethanol (β-ME) (A), cardiolipin (CL) (B), or cardiolipin plus 50 μM β-mercaptoethanol (CL+ 




without reaching the activity of the control group. In contrast to the individual 
treatment with β-mercaptoethanol or cardiolipin, the combined treatment with 
these agents fully recovered complex I activity (Figure 2C). These results suggest 
that impaired complex I activity in mitochondria from diabetic rats may be fully 
counteracted by supplying cardiolipin and restoring the redox state of mitochon-
drial thiols.
Figure 3. 
ROS production in liver mitochondria in FET mode with glutamate/malate as substrate (A), in RET mode 
with succinate as substrate (B), and in RET mode blocked with rotenone (C). Data are presented as the 
mean ± standard error of n = 6. *P < 0.05 vs. control group (Student’s t-test).
Figure 4. 
Effect of cardiolipin (CL) plus 50 μM β-mercaptoethanol (β-ME) on ROS production in FET mode in liver 
mitochondria from diabetic rats. Data are presented as the mean ± standard error of n = 6. *P < 0.05 vs. 
Control; #P < 0.05 vs. Diabetes (Student’s t-test).
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3.3 Effect of respiratory substrates on ROS production by complex I
ROS production was determined in isolated liver mitochondria in FET mode 
using glutamate/malate as substrate for complex I (Figure 3A), in RET mode using 
succinate as complex II substrate (Figure 3B), and with succinate plus rotenone 
(an inhibitor of the ubiquinone-binding site in the complex I) for blocking ROS 
production in the complex I by RET (Figure 3C). In FET mode, ROS production 
increased 1.4 - fold in mitochondria from diabetic rats in comparison to mitochon-
dria from control rats (Figure 3A). No statistically significant changes in ROS 
production were observed neither in RET mode (Figure 3B), nor when RET was 
blocked with rotenone (Figure 3C).
A 19 – fold decrease in ROS production in FET mode was observed in mito-
chondria from diabetic rats treated with cardiolipin plus β-mercaptoethanol when 
compared with mitochondria from diabetic rats without any addition (Figure 4). 
These results indicate that diabetes increases ROS production in FET mode, which 
may be prevented by reducing mitochondrial thiols and supplying mitochondria 
with cardiolipin.
4. Discussion
The results show that, under our experimental conditions, STZ-induced diabetic 
rats developed hyperglycemia and abnormal liver weight (Figure 1). These events 
were accompanied by decreased complex I activity (Figure 2) and increased ROS 
generation in FET mode (Figure 3), which was reverted by the in vitro treatment 
with cardiolipin plus β-mercaptoethanol (Figure 4). Increased liver weight has been 
identified as an alteration characterizing liver disease [20]. Moreover, increased 
blood markers of liver injury have been observed in STZ-induced diabetic rats [1]. 
All these data indicate that diabetic rats in this study developed liver disease.
There is a close relationship between the development of liver disease and the 
presence of mitochondrial dysfunction [21]. This agrees with enhanced liver weight 
(Figure 1B and C), decreased complex I activity (Figure 2A), and higher ROS 
production (Figure 3A) observed in liver mitochondria from diabetic rats. There 
are two main mechanism modulating complex I activity: the first one is the revers-
ible oxidation of reactive thiols in cysteine residues due to decreased mitochondrial 
GSH/GSSG ratio. The inhibition of the complex I by thiol oxidation can be reversed 
in vitro by increasing the concentration of GSH via the addition of thiol reducing 
agents like dithiothreitol [14]. β-mercaptoethanol is another agent that reduces GSSG 
to GSH [17], besides, it restores the activity of the ETC complexes after an oxida-
tive insult [19]. Therefore, the partial recovery of complex I activity with 50 μM 
β-mercaptoethanol (Figure 2A) suggests that thiol oxidation in the complex I is part 
of the mechanism explaining complex I inhibition by diabetes. The second mechanism 
inhibiting complex I activity is the loss of cardiolipin due to peroxidative damage. An 
approach to recover impaired complex I activity after cardiolipin loss is the exogenous 
addition of this phospholipid to isolated mitochondria [18]. This strategy partially 
recovered complex I activity in liver mitochondria of diabetic rats (Figure 2B).
The partial recovery of complex I activity with either β-mercaptoethanol or 
cardiolipin led us to think that the combined treatment with these two agents may 
drive to full recovery of complex I activity in liver mitochondria from diabetic rats, 
which was confirmed in the experiment of the Figure 2C. These data suggest that 
diabetes impaired complex I activity by promoting both the oxidation of reac-
tive thiols in the complex I and the peroxidation of cardiolipin. This suggestion is 
supported by previous data showing decreased GSH/GSSG ratios and increased 
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lipid peroxidation in liver mitochondria from STZ-induced diabetic rats [9]. As 
mentioned before, decreased GSH levels lead to the oxidation of reactive thiols in 
the complex I [14], while lipid peroxidation affects negatively both the structure 
and function of cardiolipin in the inner mitochondrial membrane [13].
We acknowledge that one of the main limitations of this study is that we did 
not measure neither cardiolipin levels nor the redox status of thiols in the complex 
I. Nevertheless, we believe that our results give a clue about the role of cardiolipin 
and thiol oxidation in the mechanism of complex I inhibition by diabetes, since the 
experimental approaches used in this study to replenish cardiolipin in mitochondria 
and to reduce thiols in complex I have been previously validated by direct determina-
tions of both cardiolipin and the redox state of thiols in complex I [14, 18]. On the 
other hand, there are conflicting studies showing increased complex I activity [22], 
enhanced content of cardiolipin [23], and decreased superoxide production by com-
plex I [24] in liver mitochondria from STZ-induced diabetic rats. However, it must 
be pointed out that diabetes was induced in these studies by a shorter, 8 to 9 -weeks 
period, in comparison with the 12-weeks period used in this study. Thus, it can be 
hypothesized that the mechanisms responsible for such adaptive responses seen in 
shorter periods of diabetes might be impaired at longer time periods like in this study.
The complex I produces ROS in FET mode due to electron leak during electron 
transfer from NADH to ubiquinone. ROS are also produced in the complex I by 
RET mode when electrons are forced to flow from ubiquinol to NAD+ [25]. ROS are 
produced at least in two different sites of the complex I, one situated at the ubi-
quinone-binding site (IQ), and the other one located at the flavin mononucleotide 
(FMN)-binding site (IF) [16]. The significant increase in ROS levels in mitochon-
dria from diabetic rats only with a substrate for complex I (Figure 3A), suggests 
that diabetes causes an alteration in the complex I that stimulates ROS production in 
FET mode. This mode of ROS production occurs when electron transfer to ubiqui-
none is blocked at the IQ site [16]. In this regard, the access of ubiquinone to the IQ 
site is thought to occur via a cardiolipin-dependent mechanism [11]. The recovery 
of complex I activity (Figure 2) and the decrease in ROS production (Figure 4) 
observed with cardiolipin, suggest that diabetes disrupt electron transfer at the IQ 
site by a mechanism involving lipid peroxidation, as suggested by the increased 
levels of lipid peroxidation found in a previous work in liver mitochondria from 
STZ-induced diabetic rats [9]. Therefore, impaired electron flow in the IQ site 
would drive to a more reduced state of the redox centers upstream the IQ site (i.e. 
the iron–sulfur clusters and the FMN in the complex I), leading to electron leak and 
ROS generation, while the replenishment of mitochondria with cardiolipin might 
improve both the architecture of the IQ site and electron transfer to ubiquinone, 
decreasing in this way the electron leak and ROS production.
The inhibition of the complex I during diabetes is not trivial as this enzyme is 
the main mechanism to maintain high NAD+/NADH ratios [26]. High NAD+ levels 
activates sirtuins proteins, whose deacetylase activity enhances lipid and glucose 
catabolism and the antioxidant defenses in the liver [27]. On the contrary, low NAD+ 
levels impair hepatic catabolism and increases oxidative stress, leading to the devel-
opment of liver disease and insulin resistance [28]. This reflect the importance of 
preserving optimal rates of NADH oxidation by the complex I in the diabetic liver, 
which, according to our results, might be achieved by strategies simultaneously aug-
menting the levels of cardiolipin and GSH. In this regard, it has been demonstrated 
that linoleic acid supplementation increases cardiolipin levels in cultured fibroblasts 
depleted of cardiolipin [29] and increases complex I activity in HeLa cells [30]. On 
the other hand, phytochemicals like betaine and β-sitosterol have counteracted the 
negative impact of liver toxicants like ethanol or carbon tetrachloride on the levels 
of mitochondrial GSH [31, 32]. Therefore, the concomitant targeting of cardiolipin 
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and mitochondrial GSH and its impact on both the complex I function and hepatic 
lipid metabolism deserves further investigation, given the central role of defective 
hepatic lipid metabolism in peripheral insulin resistance in diabetes [33].
5. Conclusions
Diabetes induced anormal liver weight in STZ-induced rats, accompanied of 
mitochondrial alterations in the ETC such as decreased complex I activity and 
increased ROS production in FET mode. These mitochondrial abnormalities were 
corrected by the in vitro treatment with cardiolipin plus β-mercaptoethanol, which 
suggest that alterations in the content of cardiolipin and thiol oxidation may be 
underlying causes of these mitochondrial alterations. On this basis, is proposed that 
therapies counteracting mitochondrial alterations in cardiolipin and thiol oxidation 
might be useful to ameliorate hepatic disturbances elicited by diabetes.
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